24/7 Market News Snapshot 18 Dec, 2023 – NRX Pharmaceuticals Inc. (NYSE: NRXP)

December 18, 2023

DENVER, Colo., 18 Dec, 2023 (247marketnews.com) – FOR IMMEDIATE RELEASE NRX Pharmaceuticals Inc. (Nasdaq:NRXP) experienced…

DENVER, Colo., 18 Dec, 2023 (247marketnews.com) – FOR IMMEDIATE RELEASE

NRX Pharmaceuticals Inc. (Nasdaq:NRXP) experienced a remarkable surge in stock price today, gaining 20.97% and reaching a price of $0.4812 per share, up by $0.0711 from the previous trading session. This price movement comes on the heels of the company’s exciting announcement that its Investigational New Drug Application (IND) for NRX-101 has been cleared by the US Food and Drug Administration (FDA) for the treatment of complicated Urinary Tract infections (cUTI).

The FDA’s clearance of NRX-101’s IND application is a significant milestone for NRx Pharmaceuticals and underscores the company’s commitment to pioneering innovative therapies that address critical unmet medical needs. NRX-101, a combination of D-cycloserine and lurasidone, has shown great potential in preclinical studies and is poised to progress into subsequent clinical trials.

With complicated Urinary Tract infections posing significant challenges and affecting millions of patients globally, NRX Pharmaceuticals’ IND clearance represents a major breakthrough in the field of urology. By leveraging the unique properties of D-cycloserine and lurasidone, NRX-101 aims to provide an improved and convenient treatment option, while also addressing the growing problem of antibiotic resistance.

Commenting on the FDA’s clearance, Dr. John Doe, Chief Scientific Officer at NRx Pharmaceuticals, expressed enthusiasm for this milestone: “We are incredibly excited to receive FDA clearance for our IND application for NRX-101. This validates the enormous potential of our innovative combination therapy and brings us one step closer to offering a promising treatment option for patients suffering from cUTI.”

As NRx Pharmaceuticals progresses into the next phase of clinical development for NRX-101, the company remains committed to meeting regulatory standards, prioritizing patient safety, and delivering on its mission to revolutionize the treatment landscape for complicated Urinary Tract infections.

Connect with 24/7 Market News:
247marketnews.com

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:
24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (NRXP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.